Press Releases | See also Media Appearances below
MedShadow Foundation Celebrates #GivingTuesday Benefactor to Match All Donations by 100%
Independent nonprofit’s mission is to inform people about side effects of medicine
NEW YORK, NY, August 7th, 2018 – MedShadow Foundation, the online nonprofit that informs people about the side effects, risks and benefits of medicine, has announced the appointment of Albulena Prelvukaj as Marketing/Development Manager.
“We are thrilled to have Albulena on the MedShadow team,” says Suzanne B. Robotti, founder Continue Reading →
August 2, 2018, New York, NY – MedShadow has received a 2018 dotCOMM Platinum designation in the nonprofit website category. dotCOMM Awards is an international competition honoring excellence in web creativity and digital communication. The competition is unique in that it reflects the role of creatives in the dynamic web Continue Reading →
March 15th, 2018, New York, NY – MedShadow Foundation has received an Honorable Mention in the 2018 AVA Digital awards for Nonprofit Web-Based Production. The AVA Digital Awards honor the ways in which marketers and communications professionals engage audiences using the digital arts, technology, and shared information. Continue Reading →
Gout is one of the most painful types of arthritis. While medications can help, lifestyle and dietary changes can minimize flare-ups and the use of drugs.
Gout has a name-recognition problem. Even though its prevalence is increasing dramatically in the US, many physicians don’t recognize how serious the condition can Continue Reading →
So what makes you afraid to get a flu shot? Most of the time those fears are based on myths, half-truths or fictitious ideas you may have heard or read about. I’d like to address some of these and explain why getting a flu shot is good not only for Continue Reading →
RadioMD Wellness For Life features an interview with Su Robotti, founder/president, MedShadow Foundation on endocrine disruptors. Click here to listen.
Contact: Julie@medshadow.org / 347-239-0249
Members of two FDA advisory committees on Wednesday narrowly favored approval for SpecGx’s putatively abuse-deterrent oxycodone product MNK-812, with plenty of arguments both for and against. Su Robotti, founder/president, MedShadow who serves as the Consumer Representative on the FDA Drug Safety and Risk Management Advisory Committee comments. Continue reading.
Julie Continue Reading →